Oxford BioMedica (OXB) Earns Buy Rating from Peel Hunt

Peel Hunt reiterated their buy rating on shares of Oxford BioMedica (LON:OXB) in a report issued on Wednesday.

Oxford BioMedica stock opened at GBX 10.96 ($0.15) on Wednesday. Oxford BioMedica has a 1-year low of GBX 4.44 ($0.06) and a 1-year high of GBX 13.19 ($0.19).

How to Become a New Pot Stock Millionaire

In other Oxford BioMedica news, insider Peter Nolan purchased 371,450 shares of the business’s stock in a transaction on Thursday, April 5th. The shares were bought at an average cost of GBX 11 ($0.15) per share, for a total transaction of £40,859.50 ($57,354.72). Also, insider Lorenzo Tallarigo purchased 22,066 shares of the business’s stock in a transaction on Thursday, March 22nd. The stock was acquired at an average price of GBX 12 ($0.17) per share, for a total transaction of £2,647.92 ($3,716.90). Over the last 90 days, insiders acquired 415,637 shares of company stock worth $4,616,194.

COPYRIGHT VIOLATION WARNING: “Oxford BioMedica (OXB) Earns Buy Rating from Peel Hunt” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3337328/oxford-biomedica-oxb-earns-buy-rating-from-peel-hunt.html.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Randgold Resources  Given a $100.00 Price Target at Desjardins
Randgold Resources Given a $100.00 Price Target at Desjardins
The J.M. Smucker  Cut to “Sell” at Credit Suisse Group
The J.M. Smucker Cut to “Sell” at Credit Suisse Group
Sensient Technologies  Earning Somewhat Positive News Coverage, Study Finds
Sensient Technologies Earning Somewhat Positive News Coverage, Study Finds
Holly Energy Partners  Given Daily Media Impact Rating of 0.15
Holly Energy Partners Given Daily Media Impact Rating of 0.15
Armstrong World Industries  Receiving Somewhat Positive Press Coverage, Study Finds
Armstrong World Industries Receiving Somewhat Positive Press Coverage, Study Finds
Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings


Leave a Reply

© 2006-2018 Ticker Report. Google+.